Clinical relevance of health-related quality of life outcomes with darifenacin

BJU International

Volumn 102, Issue 2, 2008, Pages 208-213

  Abrams, Paul ^b   Kelleher, Con ^c   Huels, Jasper ^a   Quebe Fehling, Erhard ^a   Omar, Mohamed A ^a   Steel, Michael ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b SOUTHMEAD HOSPITAL   (United Kingdom)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Darifenacin; Health related quality of life; King's Health Questionnaire; Minimum Important Difference; Overactive bladder

Indexed keywords

DARIFENACIN; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OVERACTIVE BLADDER; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; BENZOFURANS; COHORT STUDIES; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PYRROLIDINES; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE;

EID: 45449084279     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.07523.x     Document Type: Article

References (16)

1. Abrams P, Cardozo L, Fall M et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Urology 2003 61 : 37 49
2. Abrams P, Kelleher CJ, Kerr LA, Rogers RG. Overactive bladder significantly affects quality of life. Am J Manag Care 2000 6 (11 Suppl. S580 90
3. Hu TW, Wagner TH, Bentkover JD, Leblanc K, Zhou SZ, Hunt T. Costs of urinary incontinence and overactive bladder in the United States: a comparative study. Urology 2004 63 : 461 5
4. Diokno A, Sand P, Labasky R et al. Long-term safety of extended-release oxybutynin chloride in a community-dwelling population of participants with overactive bladder: a one-year study. Int Urol Nephrol 2002 34 : 43 9
5. Kelleher CJ, Reese PR, Pleil AM, Okano GJ. Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. Am J Manag Care 2002 8 (19 Suppl. S608 15
6. Kelleher CJ, Kreder KJ, Pleil AM, Burgess SM, Reese PR. Long-term health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. Am J Manag Care 2002 8 (19 Suppl. S616 30
7. Kelleher CJ, Cardozo LD, Chapple CR, Haab F, Ridder AM. Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU Int 2005 95 : 81 5
8. Reese PR, Pleil AM, Okano GJ, Kelleher CJ. Multinational study of reliability and validity of the King's Health Questionnaire in patients with overactive bladder. Qual Life Res 2003 12 : 427 42
9. Hay-Smith J, Herbison P, Ellis G, Morris A. Which anticholinergic drug for overactive bladder symptoms in adults? Cochrane Database Syst Rev 2005 3 : CD005429
10. 3 selective receptor antagonist, in the treatment of overactive bladder. BJU Int 2005 95 : 993 1001
11. Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol 1997 104 : 1374 9
12. 3 selective receptor antagonist, improves quality of life in patients with overactive bladder. Prog Urol 2004 14 (Suppl. 3 22 (Abstract 67)
13. Abrams P, Avery K, Gardener N, Donovan J, ICIQ Advisory Board. The International Consultation on Incontinence Modular Questionnaire: http://www.iciq.net. J Urol 2006 175 : 1063 6
14. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 1989 10 : 407 15
15. Kelleher CJ, Pleil AM, Reese PR, Burgess SM, Brodish PH. How much is enough and who says so? BJOG 2004 111 : 605 12
16. Brown JS, McGhan WF, Chokroverty S. Comorbidities associated with over active bladder. Am J Manag Care 2000 6 (11 Suppl. S574 9